Pluribus Labs’s Abiomed Inc ABMD Stock Holding History

Pluribus Labs’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-928	Closed	-$333K	–	240
2021 Q4	$333K	Buy	+928	New	+$314K	0.35%	115

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pluribus Labs's ABMD Position: Q1 2022 in Review

Pluribus Labs sold out of Abiomed Inc (ABMD) in Q1 2022, closing a stake of 928 shares — an estimated $333K sold.

Pluribus Labs first reported a position in ABMD in Q4 2021 and held it in 1 quarter. The position peaked at $333K in Q4 2021. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

Pluribus Labs reported no remaining Abiomed Inc position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 928 Abiomed Inc shares in Q1 2022, an estimated $333K.
Pluribus Labs first reported a position in Abiomed Inc in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Abiomed Inc position peaked at $333K in Q4 2021.
500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.